Moving on up: Second-Line Agents as Initial Treatment for Newly-Diagnosed Patients with Chronic Phase CML [0.03%]
二线药物作为新诊断的慢性期CML患者的一线治疗药物的发展趋势分析
Marie P Shieh,Masato Mitsuhashi,Michael Lilly
Marie P Shieh
The treatment of chronic myelogenous leukemia (CML) was revolutionized by the development of imatinib mesylate, a small molecule inhibitor of several protein tyrosine kinases, including the ABL1 protein tyrosine kinase. The current second g...
Neonatal systemic juvenile xanthogranuloma with an ominous presentation and successful treatment [0.03%]
凶险起病的新生儿全身性系统性幼年黄色肉芽肿病例及治疗体会
Rong Fan,Jihong Sun
Rong Fan
This case report originated from a case of neonatal multisystemic juvenile xanthogranuloma (JXG). The patient presented with blue muffin rush, cervical mass, bone destruction, lung nodule, hepatosplenomegaly, and coagulopathy and was succes...
Amanda M Sherrod,Adam Brufsky,Shannon Puhalla
Amanda M Sherrod
Gemcitabine is a chemotherapeutic agent used for the treatment of a number of malignancies. Although its major dose-limiting side effect is myelosuppression, many pulmonary toxicities have been described with its use. Severe pulmonary toxic...
Safety and efficacy of vinorelbine in the treatment of non-small cell lung cancer [0.03%]
长春地辛治疗非小细胞肺癌的疗效及安全性评估
Bryan A Faller,Trailokya N Pandit
Bryan A Faller
Lung cancer remains the most frequently diagnosed cancer in the United States, excluding non-melanoma skin cancer. Non-small cell lung cancer (NSCLC) constitutes the majority (more than 80%) of lung cancer diagnoses. Systemic therapy, with ...
Bendamustine: safety and efficacy in the management of indolent non-hodgkins lymphoma [0.03%]
苯达莫司汀治疗惰性非霍奇金淋巴瘤安全性和有效性的系统综述和 meta 分析
Nishant Tageja
Nishant Tageja
Bendamustine (Treanda, Ribomustin) was recently approved by the US Food and Drug Administration (FDA) for treatment of patients with rituximab refractory indolent lymphoma and is expected to turn into a frontline therapy option for indolent...
Clinical development of cabazitaxel for the treatment of castration-resistant prostate cancer [0.03%]
卡巴他赛治疗去势抵抗性前列腺癌的临床研究进展
Che-Kai Tsao,Sonia Seng,William K Oh et al.
Che-Kai Tsao et al.
Castration resistant prostate cancer has historically been considered chemotherapy insensitive. However, the approval of estramustine phosphate, mitoxantrone, and docetaxel, over the past few decades, has challenged this notion. Despite the...
Gemcitabine: efficacy in the treatment of advanced stage nonsquamous non-small cell lung cancer [0.03%]
吉西他滨治疗晚期非鳞状非小细胞肺癌的疗效分析
Hidetoshi Hayashi,Takayasu Kurata,Kazuhiko Nakagawa
Hidetoshi Hayashi
Lung cancer is the leading cause of cancer-related death in many countries. Approximately half of the patients with non-small cell lung cancer have advanced disease and systemic chemotherapy, especially platinum-based doublets, is currently...
Marc C Chamberlain
Marc C Chamberlain
Despite advances in upfront therapy, the prognosis in the great majority of patients with glioblastoma (GBM) is poor as almost all recur and result in disease-related death. Glioblastoma are highly vascularized cancers with elevated express...
The role of T lymphocytes in cancer patients undergoing immunotherapy with autologous dendritic cells [0.03%]
自体树突细胞免疫治疗的癌症患者T淋巴细胞的作用研究
Cláudia M Rodrigues,Bruna F Matias,Eddie F C Murta et al.
Cláudia M Rodrigues et al.
Introduction: Cancer stems from mutations in specific genes that induce uncontrolled cell proliferation. Dendritic cells (DCs) are important immunologic cells and play a crucial role in the induction of an antitumour resp...
Rapid Increase of the Serum PSA Level in Response to High-Intensity Focused Ultrasound Therapy may be a Potential Indicator of Biochemical Recurrence of Low- and Intermediate-Risk Prostate Cancer [0.03%]
高强度聚焦超声治疗后血清PSA水平的迅速升高可能是低危和中危前列腺癌生化复发的潜在指标
Teruo Inamoto,Kazumasa Komura,Toshikazu Watsuji et al.
Teruo Inamoto et al.
Objectives: To determine the incidence and magnitude of the rapid increase in the serum PSA (riPSA) level after high-intensity focused ultrasound (HIFU) therapy for prostate cancer, and its correlation with clinical facto...